Zosano Pharma Corporation (ZSAN) climbed 41.09% during last trading as the stock added $0.83 to finish the day at $2.85 with about 35.15M shares changing hands, compared to its three month average trading volume of 1.2M. The $49.16M market cap company, which fluctuated between $2.02 and $3.49 during the day, currently situated 530.53% above its 52 week low of $0.45 and 0.71% away from its one year high of $3.49. The RSI of 90.61 indicates the stock is overbought at the current levels, sell for now.
Zosano Pharma Corporation, a clinical stage specialty pharmaceutical company, develops a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of various indications. The company’s product candidate is ZP-Triptan, a proprietary formulation of zolmitriptan used for the treatment of migraine, which has completed a Phase I clinical trial. Its product candidates also include ZP-PTH, a proprietary formulation of teriparatide that is used for the treatment of severe osteoporosis; and ZP-Glucagon, a proprietary formulation of glucagon that is intended for the emergency rescue of patients suffering from life-threatening, severe hypoglycemia. The company was founded in 2006 and is headquartered in Fremont, California.
Zynga Inc. (ZNGA) dropped $-0.03 to close the day at a new closing price of $2.67, a -1.11% decrease in value from its previous closing price that moved the stock 46.7% above its 52 week low of $1.84. A total of 31.62M shares exchanged hands during the day compared with its three month average trading volume of 10.01M. The stock, which fluctuated between $2.55 and $2.69 during the day, currently situated -13.31% below its 52 week high. The stock is up by 1.52% in the past one month and down by -6.32% over the past three months. With a one year target estimate of $3.27 and RSI of 54.79, the stock still has upside potential, making it a hold for now.
Zynga Inc. develops, markets, and operates social games as live services played on the Internet, social networking sites, and mobile platforms in the United States, North America, Asia, and the European Union. It offers its online social games primarily under the Slots, Words With Friends, Zynga Poker, and FarmVille franchises. The company’s games are accessible on mobile platforms, Facebook, and other social networks, as well as Zynga.com. It also provides advertising services to advertising agencies and brokers. The company was formerly known as Zynga Game Network Inc. and changed its name to Zynga Inc. in November 2010. Zynga Inc. was founded in 2007 and is headquartered in San Francisco, California.
Novavax, Inc. (NVAX) had a light trading with around 31.31M shares changing hands compared to its three month average trading volume of 6.39M. The stock traded between $1.41 and $1.73 before closing at the price of $1.62 with 14.08% change on the day. The Gaithersburg Maryland 20878 based company is currently trading 39.66% above its 52 week low of $1.16 and -80.92% below its 52 week high of $8.49. Both the RSI indicator and target price of 74.34 and $3.29 respectively, lead us to believe that it could drop over the coming weeks.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.